Clinical trial
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With…
NCT00057616 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00057616 |
|---|---|
| Title | Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. |
| Official title | Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy |
| Lead sponsor | Celgene, Industry |
| Collaborators | ICON Clinical Research Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 274 |
| Start date | Oct 1, 2002 |
| Completion | Jul 15, 2005 |
| First posted | Apr 7, 2003 |
| Last update posted | Nov 8, 2019 |
| Countries | Australia, Estonia, Germany, Latvia, Lithuania, Netherlands, South Africa, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: